GlobeNewswire by notified

Greenfield Global Ireland Ready to Supply Life Science Customers Globally

Share

New Facility Aims to Serve Local and Global Pharmaceutical Customers with High-Purity Ethanol, Ethanol Blends and Buffer Solutions

Portlaoise, Ireland, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Greenfield Global Inc., a global leader in the production of ethanol, high-purity speciality alcohols and solvents, today announced the official start of its operation in Ireland. The facility, which has been commissioned and validated, is set to supply life science customers with its Pharmco® products in Ireland, Europe and elsewhere around the world.

Located in the heart of Ireland, Greenfield is strategically positioned to serve life science customers throughout the country as well as the rest of Europe. With direct access to the Dublin port, the company is equally prepared to supply customers across the globe. The facility sources both ethanol and isopropyl alcohol from its dedicated storage tanks. The ethanol is distilled at Greenfield’s manufacturing operations in Canada before it’s shipped to Portlaoise, Ireland.

“Greenfield Global has supplied essential alcohols, solvents and bio-processing materials from our North American operations to customers in the life science industry for more than three decades, helping them improve the health of people around the world,” said Howard Field, Greenfield Global President and CEO. “I am very excited to announce that our Ireland operation is now fully validated, and we are ready to supply these mission-critical products to our pharmaceutical and biotech customers with operations globally.”

The new facility uses Good Manufacturing Practices (GMP) for International Pharmaceutical Excipient (IPEC) guidelines for the highest quality Pharmco-branded products. The Portlaoise site houses dedicated blend tanks for ethanol, isopropyl alcohol, phosphoric acid, sodium hydroxide and Citric Acid water-based solutions. It features a closed-loop piping system that connects the production tank to a bulk loading dock and filling lines in an ISO 8 cleanroom.

“Thanks to our growing team of 30 dedicated employees, we were able to get the location up and running despite only opening up our 3,800-square-metre facility in July of 2020,” said Ken Finegan, Managing Director of Greenfield Global Ireland.

The facility is equipped with in-house quality control, a microbial laboratory, USP purified water and Water for Injection (WFI) generation. Plant equipment validation was completed through Design Qualification (DQ), Installation Qualification (IQ), Operational Qualification (OQ) and Performance Qualification (PQ). Products will be stored in a temperature-monitored and -controlled warehouse before finding their way to their final destination.

“We are beyond excited to supply new and existing life science customers with Pharmco-branded products, especially in times of globally damaged supply chains as a result of the COVID-19 pandemic,” Finegan added.

Interested in learning more? Contact Ken Finegan, Managing Director, at ken.finegan@greenfield.com.

About Greenfield Global Inc.

Greenfield Global provides high-value, mission-critical raw materials, ingredients and additives that are vital to businesses, improve people’s lives and preserve the health of the planet. Greenfield is the largest ethanol producer in Canada and owns and operates five ethanol distilleries, four specialty chemical manufacturing and packaging plants and three next-generation biofuel and renewable energy R&D centers in the United States, Canada and Ireland. Founded in 1989, Greenfield continually develops more efficient and sustainable technologies and products while shrinking its own carbon footprint. From start-ups to the largest brands in the world, customers trust Greenfield’s extensive portfolio of premium products, regulatory expertise and industry-leading service. Under its Pharmco and Commercial Alcohols brands, Greenfield delivers hundreds of products to thousands of life science, food, flavor, fragrance, and beverage customers in more than 50 countries worldwide. To learn more, visit www.greenfield.com.

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Baltic Horizon Fund consolidated audited results for 202329.3.2024 10:35:00 CET | Press release

Management Board of Northern Horizon Capital AS has approved the audited financial results of Baltic Horizon Fund (the Fund) for the year 2023. The financial results remained unchanged compared to the preliminary disclosure on 15 February 2024. Executing our strategy In a challenging economic landscape characterized by inflation, interest rate volatility, and recent geopolitical events, the Fund has assessed various strategic options to navigate these complexities and ensure future growth. Over the past year, our focus has been on reshaping our strategy to foster sustainable value, concentrating efforts on avenues that promise reliable and consistent growth for our investors. In light of prevailing market conditions, we firmly believe that the execution of the ‘Modern City Life’ strategy, introduced to investors in summer 2023, is paramount to their best interests. In the coming years, we expect two thirds of the Fund’s NOI to come from the centrally located ‘Modern City Life’ multi-fu

Progress on ABN AMRO share buyback programme 22 – 28 March 202429.3.2024 08:00:00 CET | Press release

Progress on ABN AMRO share buyback programme 22 – 28 March 2024 ABN AMRO reports the transaction details related to its EUR 500 million share buyback programme announced on 14 February 2024. During the week of 22 March 2024 up to and including 28 March 2024 a total of 3,000,000 shares and depositary receipts were repurchased at an average price of €15.47 for a total amount of €46,409,760.00. For detailed information on the daily repurchased shares and depositary receipts, individual share purchase transactions and weekly reports, see the ABN AMRO website at https://www.abnamro.com/en/investor-relations/information/share-buyback-programme. To date the total consideration for shares and depositary receipts repurchased amounts to €279,519,000.00 representing 55.9% of the overall share buyback programme. ABN AMRO Press Office pressrelations@nl.abnamro.com +31 20 6288900ABN AMRO Investor Relations investorrelations@nl.abnamro.com +31 20 6282282 This press release is published by ABN AMRO Ba

Public announcement in accordance with article 7:97, §4/1 of the Belgian Companies and Associations Code (“BCAC”) concerning a capital increase by contribution in kind29.3.2024 07:00:00 CET | Press release

Press release Brussels, 29 March 2024 Regulated information – Inside information Public announcement in accordance with article 7:97, §4/1 of the Belgian Companies and Associations Code (“BCAC”) concerning a capital increase by contribution in kind On 20 November 2023, Orange Belgium SA (the “Company”) received notification from Nethys SA (“Nethys”) of its wish to contribute its 25% + 1 shareholding in VOO Holding SA (“VOO”) to the capital of the Company, provided that such contribution results in Nethys holding at least 11% of the Company's share capital (after contribution), pursuant to the provisions of the shareholders' agreement entered into by and between the Company, Atlas Services Belgium SA (“ASB”) and Nethys on 2 June 2023. Nethys can be considered a “related” party to the Company within the meaning of the IAS standards, as it has significant influence over VOO within the meaning of IAS and VOO is part of the group to which the Company belongs. Date and value of the planned t

McWhorter Foundation Combats Nelson Peltz’s Outdated Ideologies and Advocates for Sustainable Inclusivity In Corporate Leadership29.3.2024 06:59:56 CET | Press release

PALM BEACH, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- C.K. McWhorter, chairman of the McWhorter Foundation, voices concerns over outdated perspectives in corporate leadership, exemplified by recent remarks from Nelson Peltz regarding Disney's film direction. After encountering instances of racism and exclusivity on Town of Palm Beach Island (known as home to Jeffrey Epstein, Nelson Peltz and others), McWhorter reflects on the disconnect between elite boardroom discussions and the realities faced by diverse communities. While briefly meeting Nelson Peltz and shaking hands after both departed separate lunches, McWhorter initially respected his insights. However, recent comments made by Peltz suggesting Disney should avoid inclusive films have raised eyebrows and prompted McWhorter to speak out. "It's concerning when influential figures like Peltz advocate against inclusivity in entertainment," McWhorter comments. "The future is in diversity and representation, especially as millennial a

Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates29.3.2024 05:24:27 CET | Press release

SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2023 and provided corporate updates. FINANCIAL HIGHLIGHTS Total revenue was approximately RMB1,503 million during 2023. The revenue from pharmaceutical products increased by approximately 58% compared to 2022. The sales revenue of TUOYI® (toripalimab) was approximately RMB919 million, representing an increase of approximately 25% compared to the previous year.Total research and development (“R&D”) expenses were approximately RMB1,937 million in 2023, representing a decrease of approximately 19% compared to 2022. The decrease in R&D expenses was mainly due to the strategic management of R&D investments in certain early-stage pipelines, while optimizing resource all

HiddenA line styled icon from Orion Icon Library.Eye